Background: Subarachnoid haemorrhage (SAH) is a life-threatening condition with associated brain damage. Moreover, SAH is associated with a massive release of catecholamines, which may promote cardiac injury and dysfunction, possibly leading to haemodynamic instability, which in turn may influence a patient's outcome.
Objectives: To study the prevalence of cardiac dysfunction (as assessed by echocardiography) in patients with SAH and its effect on clinical outcomes.
Design: Systematic review of observational studies.
Data Sources: We performed a systematic search over the last 20 years on MEDLINE and EMBASE databases.
Eligibility Criteria: Studies reporting echocardiography findings in adult patients with SAH admitted to intensive care. Primary outcomes were in-hospital mortality and poor neurological outcome according to the presence or absence of cardiac dysfunction.
Results: We included a total of 23 studies (4 retrospective) enrolling 3511 patients. The cumulative frequency of cardiac dysfunction was 21% (725 patients), reported as regional wall motion abnormality in the vast majority of studies (63%). Due to the heterogeneity of clinical outcome data reporting, a quantitative analysis was carried out only for in-hospital mortality. Cardiac dysfunction was associated with a higher in-hospital mortality [odds ratio 2.69 (1.64 to 4.41); P < 0.001; I2 = 63%]. The GRADE of evidence assessment resulted in very low certainty of evidence.
Conclusion: About one in five patients with SAH develops cardiac dysfunction, which seems to be associated with higher in-hospital mortality. The consistency of cardiac and neurological data reporting is lacking, reducing the comparability of the studies in this field.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/EJA.0000000000001829 | DOI Listing |
Background: The new anti-Aβ antibody drugs aducanumab and lecanemab (approved in the US, not yet in Europe) must be followed up closely and regularly long-term. Previous knowledge on progression of AD in routine clinical settings longterm is crucial when introducing new dementia medications. The Swedish national quality database on dementia/cognitive disorders, SveDem, where data on different dementia disorders at the time of the dementia diagnosis since 2007 and on mild cognitive impairment (MCI) since 2021 with annual follow-ups of MMSE scores can provide this unique information.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Yale School of Public Health, New Haven, CT, USA.
Background: The Republic of Armenia is a post-Soviet, low- and middle-income country (LMIC) in the south Caucasus region with a steadily increasing aging population. The goal of this study was to provide the first look into the national cognitive health in Armenia, considering the growing burden of cognitive impairment (CI) and widespread lack of public awareness about dementia. As a component of the early detection memory screening program launched by Alzheimer's Care Armenia's Brain Health Project and funded through Davos Alzheimer's Collaborative (DAC), this study aimed to understand the prevalence of CI and associated factors across the adult population.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
VA Boston Healthcare System, Jamaica Plain, MA, USA.
Background: Mixed dementia type - Alzheimer's Disease (AD), cerebral amyloid angiopathy (CAA), and vascular - is vastly recognized as a cause of dementia in older adults. Whereas CAA, primarily leptomeningeal, is a frequent complication in hereditary transthyretin cardiac amyloidosis (TTRCA), it is unusually reported in association with wild-type TTR, with or without polyneuropathy. The knowledge of mixed dementia and wild-type TTR association is even scarcer.
View Article and Find Full Text PDFThe recent ACHIEVE study (https://www.achievestudy.org/) demonstrated the substantial benefit of hearing aid use in those with mild-moderate hearing loss and at increased risk for cognitive decline.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Laboratory of Neuro Imaging (LONI), University of Southern California, Los Angeles, CA, USA.
Background: Anti-amyloid therapy appears to have an increased effect on reducing cognitive decline in amyloid- and tau-positive individuals. However, clinical trials inclusion criteria require solely amyloid positivity. Herein, we developed a machine-learning prediction model to identify tau positivity in amyloid-positive individuals using clinical variables.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!